KALA PHARMACEUTICALS INC's ticker is KALA and the CUSIP is 483119103. A total of 123 filers reported holding KALA PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 3.55 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $72,000 | -81.6% | 59,719 | -60.1% | 0.00% | – |
| Q3 2021 | $392,000 | -81.5% | 149,513 | -62.6% | 0.00% | -100.0% |
| Q2 2021 | $2,117,000 | -32.7% | 399,464 | -14.4% | 0.00% | 0.0% |
| Q1 2021 | $3,145,000 | -2.6% | 466,712 | -2.0% | 0.00% | 0.0% |
| Q4 2020 | $3,228,000 | -9.8% | 476,019 | -0.2% | 0.00% | -50.0% |
| Q3 2020 | $3,579,000 | -28.6% | 477,085 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $5,014,000 | +19.2% | 477,085 | -0.4% | 0.00% | 0.0% |
| Q1 2020 | $4,207,000 | +138.1% | 478,891 | 0.0% | 0.00% | +100.0% |
| Q4 2019 | $1,767,000 | -4.0% | 478,891 | -0.9% | 0.00% | 0.0% |
| Q3 2019 | $1,840,000 | -35.3% | 483,374 | +8.4% | 0.00% | 0.0% |
| Q2 2019 | $2,844,000 | +20.2% | 446,003 | +55.8% | 0.00% | 0.0% |
| Q1 2019 | $2,367,000 | +89.2% | 286,184 | +11.9% | 0.00% | 0.0% |
| Q4 2018 | $1,251,000 | -19.3% | 255,760 | +62.7% | 0.00% | 0.0% |
| Q3 2018 | $1,551,000 | – | 157,169 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CAXTON CORP | 1,727,751 | $4,527,000 | 3.67% |
| RA Capital Management | 10,874,613 | $28,491,000 | 0.40% |
| ACT CAPITAL MANAGEMENT, LLC | 190,000 | $498,000 | 0.26% |
| Samsara BioCapital, LLC | 601,162 | $1,575,000 | 0.25% |
| Orbimed Advisors | 3,438,998 | $9,010,000 | 0.10% |
| Towercrest Capital Management | 122,500 | $321,000 | 0.06% |
| Knights of Columbus Asset Advisors LLC | 236,757 | $620,000 | 0.06% |
| Matisse Capital | 56,100 | $147,000 | 0.05% |
| Taylor Wealth Management Partners | 43,990 | $115,000 | 0.04% |
| SYMONS CAPITAL MANAGEMENT INC | 14,346 | $37,000 | 0.02% |